Printer-Friendly      

Trial of Celecoxib in Amyotrophic Lateral Sclerosis

Study Purpose:

To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS).

Disease:

Amyotrophic Lateral Sclerosis (ALS),  Familial ALS,  Sporadic ALS

Study Type:

Interventional Trial

Study Category:

Drug Trial

Study Status:

Not enrolling

Phase:

Study Chair(s)/Principal Investigator(s):

Merit Cudkowicz, Massachusetts General Hospital

Clinicaltrials.gov ID (11 digit #):

Neals Affiliated?

Yes

Coordinating Center Contact Information


.(JavaScript must be enabled to view this email address)
.(JavaScript must be enabled to view this email address)

Full Study Summary:

Study Sponsor:

Participant Duration:

12 months

Estimated Enrollment:

300

Estimated Study Start Date:

06/01/2001

Estimated Study Completion Date:

06/30/2003

Posting Last Modified Date:

05/09/2019

Date Study Added to alsconsortium.org:

05/09/2019
  • Eligibility Criteria

    Gender:

    Female, Male

    Minimum Age:

    N/A

    Maximum Age:

    N/A

    Time since Symptom Onset:

    Time since Diagnosis:

    Can participants use Riluzole?


  • Site Contact Information
  • Study Results

    Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival. Celecoxib was well tolerated and was not associated with an increased frequency of adverse events. Prostaglandin E(2) levels in cerebrospinal fluid were not elevated at baseline and did not decline with treatment.

    Full Study Results